The themes Tscan Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Tscan Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$0.16-1.6%Nov 13 close
The latest quarter (ended September 30, 2026) is from Tscan Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Tscan Therapeutics files it.
Grade F-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 19 quarters of Tscan Therapeutics, Inc.’s grade history. The other 17 go back to May 2022.